Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This locally-acting androgen receptor (AR) antagonist is a small molecule therapeutic being developed by Nanjing Cuccess Pharmaceutical (and its subsidiary Hanxin Pharmaceutical). The drug is designed to block androgen receptor signaling specifically at local tissues, such as the skin or prostate, potentially minimizing systemic side effects associated with traditional AR antagonists. While specific clinical data is limited, the mechanism of action suggests applications in androgen-mediated conditions including dermatological disorders like acne or androgenetic alopecia, as well as prostate-related diseases. The compound is currently in the research and development stage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on locally-acting androgen receptor antagonist.